Metaphedrine
| Clinical data | |
|---|---|
| Other names | 3-Methyl-N-methylamphetamine; 3-MMA; 3MMA; 3-Me-MA; Metaphedrine |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C11H17N |
| Molar mass | 163.264 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Metaphedrine, or 3-methylmethamphetamine (3-MMA), is a methamphetamine derivative which has been sold as a designer drug, with the substance first encountered online in 2020 and reported in Sweden in 2021. It is a potent monoamine reuptake inhibitor and is thought to have psychostimulant effects. The drug was not active as a serotonin 5-HT2A receptor agonist.